Sequential administrations of PCV-13–PPV-23 among immunocompromised adults based on ACIP recommendation
| Pneumococcal vaccine-naive immunocompromised* adult persons | ||||
| First vaccine | Interval between two vaccines | Second vaccine | ||
| PCV-13 | ≥8 weeks | PPV-23 | ||
| Previously PPV-vaccinated immunocompromised adult persons ≥65 years | ||||
| First vaccine | Interval between two vaccines | Second vaccine | ||
| PPV-23 | ≥1 year | PCV-13 | ||
| Previously received PPV-23 in immunocompromised adults, when aged <65 years | ||||
| First vaccine before age 65 | Interval between first PPV-23 and PCV-13 | Second vaccine | Interval between PCV-13 and second PPV-23 | Third vaccine |
| PPV-23 | ≥1 year | PCV-13 | ≥8 weeks | PPV-23 |
| Interval between first and second PPV-23 vaccine: ≥5 years | ||||
*Immunocompromised conditions are defined as: congenital or acquired immunodeficiency, human immunodeficiency viral infection, chronic renal failure, nephrotic syndrome, leukaemia, lymphoma, Hodgkin disease, generalised malignancy, iatrogenic immunosuppression, solid organ transplant, multiple myeloma.
ACIP, Advisory Committee on Immunization Practices; PCV-13, pneumococcal conjugate vaccine with 13 serotypes; PPV-23, pneumococcal polysaccharide vaccine with 23 serotypes.